Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Evolution of Copernicus Land Services based on Sentinel data (ECoLaSS)

Framework: Horizon 2020 — Industrial Leadership
Programme: Space
Theme: Enabling exploitation of space data
Action type: Research and Innovation actions
Countries involved: Austria,Germany,Germany,Belgium,France
Call: Evolution of Copernicus services (H2020-EO-2016, 2016)
Start date: 2017-01-01
End date: 2019-12-31
Duration (months): 36.0
Total project cost (EUR): 2000000.0
EU funding (EUR): 2000000.0
Participants: 5
Project status: CLOSED

The Copernicus programme, coordinated and managed by the European Commission, delivers environmental information (largely based on Earth Observation satellite data) in the form of Copernicus Services, addressing six thematic areas: Land, Marine, Atmosphere, Climate Change, Emergency Management and Security. The new Sentinel satellites, recently extended through the successful launch of Sentinel-3, will deliver an unprecedented volume of EO data in high spatial, radiometric and temporal resolution, providing a huge potential for monitoring applications within the Land Monitoring Service - at continental and global scale. The synergistic use of Sentinel-1/2/3 opens up the possibility for new applications, such as the use of time series in the area of Land Monitoring. The ECoLaSS project (Evolution of Copernicus Land Services based on Sentinel data) aims to develop methods and algorithms for pre-operational prototypes improving and developing future specific Copernicus Land services. These prototypes, representing new or improved Copernicus Land Cover and Land Use products, will be demonstrated by means of test/demonstrations sites distributed over Europe and Africa, representing multiple bio-geographic regions and biomes. Prototypes will be designed with high spatial and thematic accuracy, in a timely manner for a pan-European operational Roll-out with the potential for global applications. ECoLaSS will promote the innovation potential of new land monitoring services and applications and might thus contribute to a growing “Copernicus Economy” by boosting (new) Copernicus CORE Land Services and value-added applications (Downstream Services). It is expected, that such new services will bring new opportunities with a wide range of dedicated applications to the market from 2020 onwards and thus significantly contribute to a positive evolution of the Copernicus Land services.

Keywords: applications,land services,land cover and land use,monitoring,sentinel data,time series
ShaMROCK – Secure professional Mobile Radio Over Commercial networKs (ShaMROCK)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure societies - protecting freedom and security of Europe and its citizens
Action type: SME instrument
Countries involved: Spain
Call: Engaging SMEs in security research and development (H2020-SMEINST-2-2016-2017, 2016)
Start date: 2016-09-01
End date: 2018-10-31
Duration (months): 26.0
Total project cost (EUR): 1835445.0
EU funding (EUR): 1284811.5
Participants: 1
Project status: CLOSED

Of absolute critical importance to the overall security of citizens, are the emergency services and the communication networks that they utilize. ShaMROCK will leverage the unique experience, skills and patented Push To Talk (PTT) technologies of Genaker in order to deliver the World´s first broadband Professional Mobile Radio (PMR) system running over standard cellular networks. Such a system is just starting to be demanded by International Governments for usage by Emergency Services and Professionals to firstly, reduce costly dependency on dedicated networks, to secondly, increase communication resilience and cross-border management and thirdly, to support a new generation of point-of-use security and infrastructure protection applications. Genaker is a European SME with a unique voice, video and data group communications cloud platform. Currently with a solution for Professional customers, we have now successfully completed an SME Instrument phase 1 feasibility study that validated the technical and business potential that we have for moving our solution to the Mission Critical need. We now intend to drive our new product development and its advanced prioritization and Quality-Of-Service engine to TRL9, to continue to patent our new IPR, to deeply test in targeted stakeholder pilots and to continue to update our go-to-market plan through direct Market and Technology watches. ShaMROCK Project will form a key milestone in Genaker´s plans to execute this identified high-value business opportunity which has the clear capacity to greatly increase our sales, to capture further investment and to further drive our SME to the global security stage.

Keywords: market demand user needs emergency service mobile ptt push to talk over cellular poc,broadband secure comms mission critical group voice communication traffic over lte
A Clinical Phase IIB trial with 2OHOA in patients with newly-diagnosed malignant glioma. (CLINGLIO)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: Research and Innovation actions
Countries involved: Spain,Spain,Italy,Italy,Israel,Hungary,France,Netherlands,United States,United Kingdom,United Kingdom
Call: New therapies for rare diseases (H2020-SC1-2017-Two-Stage-RTD, 2017)
Start date: 2017-12-01
End date: 2022-05-31
Duration (months): 54.0
Total project cost (EUR): 6155125.0
EU funding (EUR): 6155125.0
Participants: 13
Project status: CLOSED

Glioma is a rare brain cancer with one of the highest mortality rates. It is considered an orphan disease due to its low prevalence (less than 0.5 cases per 10,000 inhabitants in the EU) and the lack of plausible therapies. Based on the discovery of the lipid proliferation switch (high membrane PE-to-SM molar ratio that enables recruitment of cell growth transducers to the membrane), the SME Lipopharma (leading this application) defined a novel anticancer drug target, the tumor repressor protein sphingomyelin synthase 1 (SMS1). An innovative SMS1 activator, 2OHOA, was designed and showed safety and efficacy in preclinical GLP and non-GLP studies. A first-in-man clinical trial I/IIa (ClinicalTrials.gov identifier #NCT01792310) further demonstrated its safety and efficacy in humans. The European Medicines Agency (EMA) designated 2OHOA orphan drug for the treatment of glioma and approximately half of the patients with glioma submitted to >2 months of treatment showed positive response. The present project aims to perform a clinical phase IIB study to demonstrate 2OHOA’s efficacy against glioblastoma multiforme, the most aggressive form of glioma. In this context, a written formal report from the EMA after scientific advice and protocol assistance (SA/PA-EMA/CHMP/SAWP773534/2014) indicates that 2OHOA would obtain Conditional Marketing Authorisation if this phase-IIB study further demonstrates statistically significant efficacy. In addition this project will further investigate 2OHOA’s safety, mechanism of action and biomarkers for glioblastoma diagnosis, prognosis and response to 2OHOA treatment. These studies will let us (i) know the molecular basis underlying the response to 2OHOA treatment, (ii) define new biomarkers, (iii) design more efficacious personalized treatments and (iv) investigate therapeutic alternatives in patients who do not respond to treatment.

Keywords: glioblastoma,brain cancer,deadly conditions,minerval,innovative mechanism of action
Simple fusion systems and linking systems (FusionSystems)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Mathematics
Countries involved: United Kingdom
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2015, 2015)
Start date: 2016-08-03
End date: 2018-08-02
Duration (months): 24.0
Total project cost (EUR): 195454.8
EU funding (EUR): 195454.8
Participants: 1
Project status: CLOSED

The classification of finite simple groups is often regarded as one of the major mathematical achievements of the 20th century. Its importance lies not only in the fundamental result, but also in the methodology and conceptual framework developed for its proof. Most intriguingly, it turned out that the structure of a finite group is closely connected to the structure of the p-local subgroups, i.e. the normalizers of non-trivial p-subgroups, for a suitably chosen prime p. Of particular importance is the prime 2. Even though the proof of the classification of finite simple groups is insightful in its major conceptual approach, it is extremely long and difficult in its details. Thus, it would be of great interest to obtain a simplified proof. Moreover, to gain the maximum benefit from the methods of the proof of the classification, it is highly desirable to work in a more general context which in particular allows also for applications in the modular representation theory of finite groups. Saturated fusion systems provide a conceptual framework for this and connect to important questions in homotopy theory. A program to find a new and better proof of the classification of finite simple groups through a classification of simple fusion systems at the prime 2 has been recently outlined by Aschbacher. Two parts of our proposal concern classification problems for fusion systems. Their significance lies not only in completing important cases in Aschbacher's program, but also in giving new insight into the relative abundance of exotic examples, i.e. fusion systems not induced by any finite group. In the third part we attack a major problem in the algebraic theory of fusion systems by defining an analogue in fusion systems of centralizers of subgroups of finite groups. This will simultaneously facilitate a classification of fusion systems in the spirit of Aschbacher's program, and lead to a combinatorial understanding of maps between classifying spaces of fusion systems.

Keywords: finite group theory,fusion systems,related homological algebra and homotopy theory
Accelerating mass loss of Greenland: firn and the shifting runoff limit (CASSANDRA)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Earth system science
Panel description: Physical geography, geology, geophysics, atmospheric sciences, oceanography, climatology, cryology, ecology, global environmental change, biogeochemical cycles, natural resources management
Countries involved: Switzerland
Call: ERC Consolidator Grant (ERC-2018-COG, 2018)
Start date: 2019-05-01
End date: 2024-10-31
Duration (months): 66.0
Total project cost (EUR): 1989181.0
EU funding (EUR): 1989181.0
Participants: 1
Project status: SIGNED

Meltwater running off the flanks of the Greenland ice sheet contributes roughly 60% to its mass loss, the rest being due to calving. Only meltwater originating from below the elevation of the runoff limit leaves the ice sheet, contributing to mass loss; melt at higher elevations refreezes in the porous firn and does not drive mass loss. Therefore any shift in the runoff limit modifies mass loss and subsequent sea level rise. New evidence shows surface runoff at increasingly high elevations, outpacing the rate at which the equilibrium line elevation rises. This research proposal focuses on the runoff limit as a powerful yet poorly understood modulator of Greenland mass balance. We will track the runoff limit over the full satellite era using two of the largest and oldest remote sensing archives, Landsat and the Advanced Very High Resolution Radiometer (AVHRR). We will establish time series of the runoff limit for all regions of Greenland to identify the mechanisms driving fluctuations in the runoff limit. This newly gained process understanding and a wealth of in-situ measurements will then be used to build firn hydrology models capable of simulating runoff and the associated runoff limit over time. Eventually, the firn hydrology models will be applied to reconcile estimates of Greenland past, present and future mass balance. Covering the entire satellite era and all of Greenland, the focus on the runoff limit will constitute a paradigm shift leading to major advance in our understanding of how vulnerable the surface of the ice sheet reacts to climate change and how the changing surface impacts runoff and thus Greenland's role in the global sea level budget.
Integrated quantum correlation counter (IQCC)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Netherlands
Call: ERC Proof of Concept Grant (ERC-2014-PoC, 2014)
Start date: 2015-04-01
End date: 2016-03-31
Duration (months): 12.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

Quantum correlation measurements are essential to study and analyze the statistics of light fields, to observe quantum entanglement and are central in several emerging applications of quantum optics such as quantum cryptography, ballistic imaging, logic gates, quantum repeaters, fluorescence correlation spectroscopy and optical tomography. The measurement techniques have not evolved much since the report of the first quantum correlation measurement in 1956: macroscopic optical elements are used to divide a light beam and single photon detectors are placed in each arm, correlations among the detectors signals are then analyzed to yield correlation histograms. This implementation is bulky and prone to misalignment, when measuring higher-order correlations, the number of required components scales up exponentially. My ERC consolidator grant involves performing numerous quantum correlation measurements on light fields generated by single quantum dots coupled to atomic vapours. Here, a new architecture for a quantum correlation counter is proposed where the detectors are all integrated on a chip to offer the user a compact and robust device to measure quantum correlations up to orders as high as 4 and also able to resolve photon numbers with high fidelity. Eight contiguous superconducting single photon detectors coupled to an optical fiber will be used to achieve high detection efficiencies and unprecedented time resolution. Two prototypes of increasing complexity will be built and tested. The final system will form the starting point for a commercialization effort to be led by Single Quantum BV, a spin-off from my research group that produces single photon detectors. I expect an initial sales volume of 10 units/year to grow to 50 units/year after 5 years.

Keywords: quantum optics,nanoscience,nanotechnoloy,quantum information
Pre-commercial procurement for integrated CARE solutions addressing the Multimorbidity mATRIX in ageing populations (Carematrix PCP)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Health care provision and integrated care
Action type: Pre-Commercial Procurement
Countries involved: Spain,Spain,Sweden,Norway,Norway,Netherlands
Call: Pre-commercial procurement (PCP) for integrated care solutions (H2020-SC1-2020-Single-Stage-RTD, 2020)
Start date: 2021-03-01
End date: 2025-12-31
Duration (months): 58.0
Total project cost (EUR): 5999716.75
EU funding (EUR): 5399745.09
Participants: 7
Project status: SIGNED

Over 50m people suffer from multimorbidity (PMM) in Europe. Recent reviews find that PMM experience a range of system and professional-related issues with care delivery. In part, this is because current investments in process-based delivery means delivering healthcare within single diagnoses tracks/silos. For PMMs this does not reflect real-world conditions. No technology is available today that enables the specific care, treatment, administration and support needed for this target group. Breakthrough solutions will classify the individual according to their co/multimorbidities and medications. But this needs to be developed in close dialogue between PMM, care providers and industry sectors based upon a strong demand driven approach in a PCP. Accordingly, the CareMatrix Buyers Group (SE, NO, ES) challenge the market to develop innovative technology that enables more predictive care and support benefits for PMM. This is achieved with 6 project objectives summarised as PCP: stakeholder engagement, roadmap, Call, implementation, next steps and; profiling and outreach via IFIC. The methodology can be summarised as PCP: framing actions (PCP preparation, use of UCD principles and practice); implementation actions (Phases 1-3 contract management, support, evaluation and testing) and Market Preparation actions (business development support for Phase 3 suppliers, standards, initial PPI preparation). Direct benefits include: • 20% reduction in time spent for visits to care facilities • Improvements from baseline in at least 75% of aspects of care as identified using PREM surveys • 50% fewer patient data-related incidents (increased patient safety) between organizations • No of clinical errors reduced by 30%; Underpinning the CareMatrix solution(s) with integrated innovation (supportive policy priorities, organisational and social innovations) will optimise the potential of those solutions to produce savings of 10% in health care expenditure for PMM.

Keywords: carematrix,pre commercial procurement,multimorbidity,integrated care
Regulatory and functional architecture of 'Nested-Sensitivity' microexon programs (NESTEDMICS)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Integrative Biology: from Genes and Genomes to Systems
Panel description: Genetics, epigenetics, genomics and other ‘omics studies, bioinformatics, systems biology, genetic diseases, gene editing, innovative methods and modelling, ‘omics for personalised medicine
Countries involved: Spain
Call: ERC CONSOLIDATOR GRANTS (ERC-2020-COG, 2020)
Start date: 2021-07-01
End date: 2026-06-30
Duration (months): 60.0
Total project cost (EUR): 1974541.0
EU funding (EUR): 1974541.0
Participants: 1
Project status: SIGNED

Neural microexons are a paradigmatic example of a cell type-specific transcriptomic program. Microexons are tiny exons that we revealed to have striking neuronal specificity established by their master splicing regulator Srrm4, which activates them during neuronal differentiation. However, our unpublished data challenge this on/off regulatory and functional paradigm. We found that a related paralog, Srrm3, is lowly but significantly expressed also in endocrine pancreas and, together with Srrm4, configure a 3-step switch of Srrm3/4 activity in pancreas (low), brain (mid) and retina (high). These different levels of expression activate increasingly larger subsets of microexons in the three tissues, configuring a triple-nested microexon program. Remarkably, initial results support a model in which microexon subclass inclusion is dictated largely by their sensitivity to Srrm3/4, and each subclass is differentially enriched for distinct functional categories including vesicle-mediated transport, neuronal differentiation and cilium biogenesis. This project will assess the regulatory and functional architecture of this new paradigm by answering: (1) How are the different levels of the master regulators controlled in each cell type? (2) How are the distinct sensitivities of microexons to Srrm3/4 genomically encoded? (3) What are the functional implications of the 'nestedness' of the microexon programs? (4) How does misregulation of the nested programs contribute to disease? These goals will be achieved by a combination of high-throughput methods and focused experiments using in vitro and in vivo systems. The expected results will provide a transformative multi-level portrait of microexons, from quantitative regulatory logic to organismal functions. Moreover, this novel paradigm is likely to apply to many other master regulators, expanding the impact of the project and shedding new light into how cell type-specific transcriptomes are established in embryogenesis.

Keywords: alternative splicing,cis regulatory code,endocrine pancreas,neurobiology
Predicting Effective Adaptation to Breast Cancer to Help Women to BOUNCE Back (BOUNCE)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Methods and data
Action type: Research and Innovation actions
Countries involved: Israel,Italy,Finland,Greece,Greece,Greece,Portugal
Call: Personalised computer models and in-silico systems for well-being (H2020-SC1-2017-CNECT-2, 2017)
Start date: 2017-11-01
End date: 2022-04-30
Duration (months): 54.0
Total project cost (EUR): 4999410.0
EU funding (EUR): 4999410.0
Participants: 10
Project status: CLOSED

Coping with breast cancer more and more becomes a major socio-economic challenge not least due to its constantly increasing incidence in the developing world. There is a growing need for novel strategies to improve understanding and capacity to predict resilience of women to the variety of stressful experiences and practical challenges related to breast cancer. This is a necessary step toward efficient recovery through personalized interventions. BOUNCE will bring together modeling, medical, and social sciences experts to advance current knowledge on the dynamic nature of resilience as it relates to efficient recovery from breast cancer. BOUNCE will take into consideration clinical, cancer-related biological, lifestyle, and psychosocial parameters in order to predict individual resilience trajectories throughout the cancer continuum and eventually increase resilience in breast cancer survivors and help them remain in the workforce and enjoy a better quality of life. BOUNCE will deliver a unified clinical model of modifiable factors associated with optimal disease outcomes and will deploy a prospective multi-center clinical pilot at four major oncology centers (in Italy, Finland, Israel and Portugal), where a total of 660 women will be recruited in order to assess its clinical validity against crucial patient outcomes (illness progression, wellbeing, and functionality). The advanced computational tools to be employed will validate indices of patients’ capacity to bounce back during the highly stressful treatment and recovery period following diagnosis of breast cancer. The overreaching goal of BOUNCE is to incorporate elements of a dynamic, predictive model of patient outcomes in building a decision-support system used in routine clinical practice to provide physicians and other health professionals with concrete, personalized recommendations regarding optimal psychosocial support strategies.

Keywords: breast cancer,woman resilience building,lifestyle,environmental and psychocognitive information,prediction,cancer survivors,models,optimal psychosocial support strategies,pilots